FDA grants priority review to TAR-200, which demonstrated an 82% complete response in high-risk bladder cancer unresponsive ...

Johnson & Johnson (JNJ) gets FDA priority review for TAR-200 gains, a drug releasing system targeting bladder cancer. Read ...

Amphix Bio LLC has been granted U.S. FDA orphan drug designation for its lead candidate AMFX-200 for the treatment of acute spinal cord injury (SCI). AMFX-200 is an FGFR (fibroblast growth factor ...

The FDA prioritizes TAR-200 for treating high-risk bladder cancer, showcasing promising phase 2b study results and innovative ...

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

The New Brunswick, N.J., pharmaceutical giant on Thursday said the application covers TAR-200 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle invasive ...

Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC).